SciSparc Ltd. is a biotechnology company focused on the development and commercialization of innovative treatments for various medical conditions, particularly those related to the central nervous system
The company is engaged in advancing therapies that aim to address significant unmet needs, utilizing its proprietary platform to explore and enhance the effectiveness of cannabinoid-based treatments. Through its research and development efforts, SciSparc aims to create novel solutions that enhance patient outcomes and improve quality of life in underserved therapeutic areas.
SciSparc Ltd. shares are soaring after its merger-bound AutoMax Motors received its first shipment of JAC vehicles. The shipment positions AutoMax to begin marketing and sales activities for JAC Motors vehicles across Israel.
SciSparc Ltd. (NASDAQSPRC) announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at the Soroka Medical Center in Israel. The Israeli specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system enrolled the first patient in its clinical trial assessing the efficacy and safety of its cannabidiol (CBD) – based drug for the treatment of children with autism spectrum disorder in March.
SciSparc signs an exclusive license agreement with Polyrizon Ltd for its SCI-160 pain treatment program, with potential milestones of $3M in cash plus royalties.
